{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:13:19Z","timestamp":1787065999149,"version":"build-2736575974"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.coph.2022.102183","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T23:32:38Z","timestamp":1644881558000},"page":"102183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Eosinophilic esophagitis: New molecules, better life?"],"prefix":"10.1016","volume":"63","author":[{"given":"Angela Y.","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5918-2062","authenticated-orcid":false,"given":"Albert J.","family":"Bredenoord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2022.102183_bib1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF01296781","article-title":"Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome","volume":"38","author":"Attwood","year":"1993","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.coph.2022.102183_bib2","first-page":"1419","article-title":"Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings","volume":"124","author":"Straumann","year":"1994","journal-title":"Schweiz Med Wochenschr"},{"key":"10.1016\/j.coph.2022.102183_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.gastro.2017.06.067","article-title":"Epidemiology and natural history of eosinophilic esophagitis","volume":"154","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102183_sref4","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1053\/j.gastro.2020.02.038","article-title":"AGA Institute and the Joint Task Force on allergy-immunology practice Parameters clinical guidelines for the management of eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102183_bib5","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-019-01173-2","article-title":"Pharmacotherapies for the treatment of eosinophilic esophagitis: state of the art review","volume":"79","author":"Rooij","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2022.102183_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaci.2019.10.027","article-title":"Emerging therapies for eosinophilic esophagitis","volume":"145","author":"Greuter","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2022.102183_sref7","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/j.gastro.2018.07.009","article-title":"Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference","volume":"155","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102183_bib8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1053\/j.gastro.2017.06.065","article-title":"Pathophysiology of eosinophilic esophagitis","volume":"154","author":"O'Shea","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102183_bib9","first-page":"10","article-title":"Discovery, function, and therapeutic targeting of siglec-8","author":"Youngblood","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.coph.2022.102183_bib10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/gutjnl-2015-310991","article-title":"Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis","volume":"65","author":"Molina-Infante","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.coph.2022.102183_bib11","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1016\/j.cgh.2020.01.024","article-title":"Efficacy of therapy for eosinophilic esophagitis in real-world practice","volume":"18","author":"Laserna-Mendieta","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2022.102183_bib12","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1572-0241.2007.01179.x","article-title":"Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis","volume":"102","author":"Spechler","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2022.102183_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1572-0241.2005.40476.x","article-title":"Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment","volume":"100","author":"Calabrese","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2022.102183_bib14","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.cgh.2014.02.037","article-title":"Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis","volume":"12","author":"Rhijn","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2022.102183_bib15","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1136\/gutjnl-2012-302250","article-title":"Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD","volume":"62","author":"Cheng","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.coph.2022.102183_bib16","article-title":"Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2022.102183_bib17","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.dld.2021.05.025","article-title":"Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis","volume":"53","author":"Navarro","year":"2021","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.coph.2022.102183_bib18","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1053\/j.gastro.2020.02.039","article-title":"Technical review on the management of eosinophilic esophagitis: a report from the AGA Institute and the Joint Task Force on allergy-immunology practice Parameters","volume":"158","author":"Rank","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102183_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cgh.2015.07.041","article-title":"Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis","volume":"14","author":"Lucendo","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2022.102183_bib20","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/apt.15957","article-title":"Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry","volume":"52","author":"Laserna-Mendieta","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2022.102183_bib21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/gutjnl-2014-308815","article-title":"A\u00a0randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis","volume":"65","author":"Miehlke","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.coph.2022.102183_bib22","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/apt.15670","article-title":"Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis","volume":"51","author":"Hirano","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2022.102183_sref23","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/ajg.2017.202","article-title":"Long-term treatment of eosinophilic esophagitis with swallowed topical corticosteroids: development and evaluation of a therapeutic concept","volume":"112","author":"Greuter","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2022.102183_bib24","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2020.07.039","article-title":"Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis","volume":"159","author":"Straumann","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102183_sref25","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.cgh.2019.08.050","article-title":"Rapid recurrence of eosinophilic esophagitis activity after successful treatment in the observation phase of a randomized, double-blind, double-dummy trial","volume":"18","author":"Dellon","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2022.102183_sref26","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s41395-018-0052-5","article-title":"The natural course of eosinophilic esophagitis and long-term consequences of undiagnosed disease in a large cohort","volume":"113","author":"Warners","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2022.102183_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2022.102183_bib28","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","article-title":"An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis","volume":"141","author":"Assa\u2019ad","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102183_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.coph.2022.102183_bib30","article-title":"Plausible role of asthma biological modifiers in the treatment of eosinophilic esophagitis","volume":"13","author":"Olsen","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.coph.2022.102183_bib31","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102183_bib32","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid\u2013sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102183_bib33","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","article-title":"Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis","volume":"135","author":"Rothenberg","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2022.102183_bib34","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","article-title":"RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis","volume":"156","author":"Hirano","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102183_bib35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102183_bib36","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102183_bib37","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102183_bib38","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.coph.2022.102183_sref39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102183_bib40","series-title":"ACG 2020 Annual Meeting","article-title":"A\u00a0phase 3, randomized, 3-Part Study to investigate the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic esophagitis: results from Part A","author":"Dellon","year":"2020"},{"key":"10.1016\/j.coph.2022.102183_bib41","series-title":"Dupixent\u00ae (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings","year":"2020"},{"key":"10.1016\/j.coph.2022.102183_bib42","series-title":"UEG Week Virtual 2021","article-title":"UEG - united European gastroenterology","author":"Dellon","year":"2021"},{"key":"10.1016\/j.coph.2022.102183_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113483","article-title":"A\u00a0pilot study of omalizumab in eosinophilic esophagitis","volume":"10","author":"Loizou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2022.102183_bib44","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/j.gastro.2014.05.036","article-title":"Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE","volume":"147","author":"Clayton","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102183_bib45","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/all.12096","article-title":"Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis","volume":"68","author":"Straumann","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.coph.2022.102183_bib46","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.jaci.2018.10.066","article-title":"Siglec-8 in eosinophilic disorders: receptor expression and targeting using chimeric antibodies","volume":"143","author":"Legrand","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2022.102183_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126219","article-title":"Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis","volume":"4","author":"Youngblood","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.coph.2022.102183_bib48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000501637","article-title":"AK002, a humanized sialic acid-binding immunoglobulin-like lectin-8 antibody that induces antibody-dependent cell-mediated cytotoxicity against human eosinophils and inhibits mast cell-mediated anaphylaxis in mice","volume":"180","author":"Youngblood","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.coph.2022.102183_bib49","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti-Siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102183_bib50","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1194\/jlr.R046300","article-title":"An update on the biology of sphingosine 1-phosphate receptors","volume":"55","author":"Blaho","year":"2014","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.coph.2022.102183_bib51","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","volume":"16","author":"Peyrin-Biroulet","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coph.2022.102183_bib52","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/imm.12272","article-title":"Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond","volume":"142","author":"Garris","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.coph.2022.102183_bib53","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102183_bib54","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.01.051","article-title":"T-helper 2 cytokines, transforming growth factor \u03b21, and eosinophil products induce fibrogenesis and alter muscle motility in patients with eosinophilic esophagitis","volume":"146","author":"Rieder","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102183_bib55","first-page":"141","article-title":"Creating a multi-center rare disease consortium \u2013 the consortium of eosinophilic gastrointestinal disease researchers (CEGIR)","volume":"2","author":"Cheng","year":"2017","journal-title":"Transl Sci Rare Dis"},{"key":"10.1016\/j.coph.2022.102183_bib56","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1053\/j.gastro.2021.02.016","article-title":"In esophageal squamous cells from eosinophilic esophagitis patients, Th2 cytokines increase eotaxin-3 secretion through effects on intracellular calcium and a non-gastric proton pump","volume":"160","author":"Odiase","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102183_bib57","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.03.057","article-title":"Interleukin-15 expression is increased in human eosinophilic esophagitis and mediates pathogenesis in mice","volume":"139","author":"Zhu","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102183_bib58","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/19420862.2017.1332553","article-title":"Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis","volume":"9","author":"Vicari","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.coph.2022.102183_bib59","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nm.3281","article-title":"TSLP-elicited basophil responses can mediate the pathogenesis of eosinophilic esophagitis","volume":"14","author":"Noti","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2022.102183_bib60","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222000029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222000029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:56:17Z","timestamp":1761461777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489222000029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":60,"alternative-id":["S1471489222000029"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2022.102183","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eosinophilic esophagitis: New molecules, better life?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2022.102183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102183"}}